Search clinical trials for: Toripalimab plus Anlotinib

Total 6519 results

Shanghai Changzheng Hospital

Unknown

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE)

Gastric Cancer | Immunotherapy | Anlotinib | Toripalimab | Gastro-oesophageal Junction Cancer

China
Henan Cancer Hospital

Unknown

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Taizhou Hospital

Not yet recruiting

Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell (SCLC)

SCLC | Maintenance Treatment
Sun Yat-sen University

Recruiting

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sarcoma,Soft Tissue

China
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
Sun Yat-sen University

Active, not recruiting

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Nasopharyngeal Carcinoma | Recurrent or Metastatic Nasopharyngeal Carcinoma

China
Shen Feng

Recruiting

Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Hepatocellular Cancer

China
Hubei Cancer Hospital

Recruiting

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Henan Cancer Hospital

Recruiting

Toripalimab Plus FLOT in Locally Advanced Gastric Cancer

Chemotherapy | Immune Checkpoint Inhibitor | Locally Advanced Gastric Carcinoma

China
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Hunan Cancer Hospital
Fuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...

Recruiting

Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer

Small Cell Lung Cancer

China
Henan Cancer Hospital

Recruiting

Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer

Esophageal Cancer | Squamous Cell Carcinoma | Perioperative Period

China
Third Military Medical University

Recruiting

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC, Extensive Stage

China
Sun Yat-sen University

Not yet recruiting

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Non Clear Cell Renal Carcinoma

China
Shanghai Changzheng Hospital

Completed

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Colorectal Cancer | Immunotherapy | Sintilimab | First-line Treatment | Anlotinib | Chemo-free Therapy

China
Di Wu

Not yet recruiting

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

Undifferentiated Pleomorphic Sarcoma | Soft Tissue Sarcomas

China
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (ALTER-L004)

Non Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent
Cancer Institute and Hospital, Chinese Academy...

Unknown

To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer

Lung Cancer
Peking University People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

EGFR Positive Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer
Peking University People's Hospital
Akeso Pharmaceuticals, Inc.

Not yet recruiting

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Anlotinib | Anti-PD-1 Antibody | Advanced Pancreatic Cancer

China
Sun Yat-sen University

Active, not recruiting

Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Peking Union Medical College Hospital

Not yet recruiting

SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Anlotinib | Advanced Esophageal Squamous Cell Cancer | SHR-1210
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer

Small Cell Lung Cancer Limited Stage

China
The First People's Hospital of Lianyungang
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

Lung Neoplasms | Anlotinib | Docetaxel | S-1 | Pemetrexed

China
Sun Yat-sen University
Wuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaborators

Recruiting

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | PD-1 Treatment

China
Xijing Hospital

Not yet recruiting

Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma

Melanoma

China
Sun Yat-sen University

Not yet recruiting

ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC (CONTINUE)

Lung Cancer, Nonsmall Cell
Shanghai Chest Hospital

Unknown

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Carcinoma | Non-small Cell Lung Cancer
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China
Hunan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Hunan Provincial People's...

Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

China
Coherus Biosciences, Inc.

Not yet recruiting

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors
Hunan Province Tumor Hospital

Recruiting

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer (ATHENA)

Non-small Cell Lung Cancer

China
RemeGen Co., Ltd.

Recruiting

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

NSCLC

China
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Advanced Biliary Tract Cancer

China
AnewPharma

Unknown

CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Non-small Cell Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Neoadjuvant Therapy | Esophageal Carcinoma
Sun Yat-sen University

Recruiting

Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer (PICC)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Sun Yat-sen University

Recruiting

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Breast Cancer

China
Taizhou Hospital

Not yet recruiting

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Small Cell Lung Carcinoma

China
University of Texas Southwestern Medical Center
Genentech, Inc.; Celgene

Completed

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer | Metastatic Cancer

United States
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)

NSCLC
Qianfoshan Hospital

Recruiting

A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)

Lung Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer (ATNPA)

Locally Advanced Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer | Pancreatic Neoplasm

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Advanced Hepatocellular Carcinoma | Radiotherapy | Sorafenib | Toripalimab

China

Search clinical trials for: Toripalimab plus Anlotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations